[关键词]
[摘要]
目的 探讨百乐眠胶囊联合富马酸喹硫平片治疗轻中度抑郁症的临床疗效。方法 选取2019年6月—2020年6月天津港口医院收治的100例轻中度抑郁症患者,按照随机数字表法将全部患者分为对照组和治疗组,每组各50例。对照组口服富马酸喹硫平片,2次/d,总剂量第1天50 mg,第2天100 mg,第3天200 mg,第4天300 mg,根据患者的耐受性和临床反应保持剂量150~750 mg/d。治疗组在对照组基础上口服百乐眠胶囊,4粒/次,2次/d。两组患者连续治疗1个月。观察两组患者治疗后的总有效率,比较汉密尔顿抑郁量表(HAMD-24)评分、抑郁自评量表(SDS)评分、世界卫生组织生存质量量表(WHOQOL-BREF)评分以及血清脑源性神经营养因子(BDNF)、白细胞介素-18(IL-18)、5-羟色胺(5-HT)水平。结果 治疗后,治疗组患者的总有效率为94.00%,对照组的总有效率为78.00%,两组组间具有明显差异(P<0.05)。治疗后,两组的HAMD-24评分、SDS评分均明显降低(P<0.05);治疗后,治疗组的HAMD-24评分、SDS评分比对照组低,差异有统计学意义(P<0.05)。治疗后,两组的生理、心理、社会关系、环境评分显著升高(P<0.05),治疗后治疗组生理、心理、社会关系、环境评分升高的更明显(P<0.05)。治疗后,两组的BDNF、5-HT水平显著升高,IL-18水平显著降低(P<0.05);治疗组的BDNF、5-HT水平比对照组高,IL-18水平比对照组低,差异有统计学意义(P<0.05)。结论 百乐眠胶囊联合富马酸喹硫平片治疗抑郁症的疗效确切,可减轻临床症状,改善生活质量,调节BDNF、5-HT、IL-18水平的分泌,且安全性良好。
[Key word]
[Abstract]
Objective To investigate the clinical efficacy of Bailemian Capsules combined with Quetiapine Fumarate Tablets in treatment of mild to moderate depression. Methods Patients (100 cases) with mild to moderate depression in Tianjin Port Hospital from June 2019 to June 2020 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Quetiapine Fumarate Tablets, twice daily, the total dose was 50 mg on the first day, 100 mg on the second day, 200 mg on the third day, and 300 mg on the fourth day according to the patient's tolerance and clinical response, and the dose was maintained at 150-750 mg/d. Patients in the treatment group were po administered with Bailemian Capsules on the basis of the control group, 4 grains/time, twice daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and the HAMD-24 score, the SDS score, the WHOQOL-BREF score, and the levels of BDNF, IL-18, and 5-HT in two groups were compared. Results After treatment, the total effective rate was 94.00% in the treatment group and 78.00% in the control group, and there was significant difference between the two groups (P < 0.05). After treatment, the HAMD-24 score and SDS score of two groups were significantly reduced (P < 0.05). After treatment, the HAMD-24 score and SDS score of the treatment group were lower than those of the control group (P <0.05). After treatment, physical scores, psychological scores, social relationship scores, and environmental scores in two groups were significantly increased (P < 0.05). After treatment, physical scores, psychological scores, social relationship scores, and environmental scores in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the levels of BDNF and 5-HT in two groups were significantly increased, but the level of IL-18 in two groups were significantly decreased (P < 0.05). The levels of BDNF and 5-HT in the treatment group were higher than those in the control group, while the IL-18 level in the treatment group was lower than that in the control group (P < 0.05). Conclusion Bailemian Capsules combined with Quetiapine Fumarate Tablets is effective in treatment of mild to moderate depression, and can relieve the clinical symptoms, regulate the secretion of BDNF, 5-HT, and IL-18, improve the quality of life, with good safety.
[中图分类号]
R971
[基金项目]
北京市保健科研课题项目(京13-01号)